COST-EFFECTIVENESS ANALYSIS OF AN ADJUSTED POLYGENIC RISK SCORE IN CARDIOVASCULAR DISEASE PREVENTION

被引：0
|
作者：
Hatziandreou, E. [1 ]
Panagiotou, N. [1 ]
机构：
[1] IDNA Genom, Attica, Greece
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE159
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [31] Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease - A cost-effectiveness analysis
    Wisloff, Torbjorn
    Selmer, Randi M.
    Halvorsen, Sigrun
    Fretheim, Atle
    Norheim, Ole F.
    Kristiansen, Ivar Sonbo
    [J]. BMC CARDIOVASCULAR DISORDERS, 2012, 12
  • [32] GENERALIZED COST-EFFECTIVENESS ANALYSIS OF PHARMACEUTICAL INTERVENTIONS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN THAILAND
    Khonputsa, P.
    Veerman, J. L.
    Bertram, M.
    Vos, T.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A520 - A520
  • [33] Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease - A cost-effectiveness analysis
    Torbjørn Wisløff
    Randi M Selmer
    Sigrun Halvorsen
    Atle Fretheim
    Ole F Norheim
    Ivar Sønbø Kristiansen
    [J]. BMC Cardiovascular Disorders, 12
  • [34] A COMPUTER-SIMULATION MODEL FOR COST-EFFECTIVENESS ANALYSIS OF CARDIOVASCULAR-DISEASE PREVENTION
    JOHANNESSON, M
    HEDBRANT, J
    JONSSON, B
    [J]. MEDICAL INFORMATICS, 1991, 16 (04): : 355 - 362
  • [35] Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam
    Thi-Phuong-Lan Nguyen
    Wright, E. Pamela
    Thanh-Trung Nguyen
    Schuiling-Veninga, C. C. M.
    Bijlsma, M. J.
    Thi-Bach-Yen Nguyen
    Postma, M. J.
    [J]. PLOS ONE, 2016, 11 (05):
  • [36] Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan
    Kodera, Satoshi
    Kiyosue, Arihiro
    Ando, Jiro
    Akazawa, Hiroshi
    Morita, Hiroyuki
    Watanabe, Masafumi
    Komuro, Issei
    [J]. INTERNATIONAL HEART JOURNAL, 2017, 58 (06) : 847 - 852
  • [37] COST-EFFECTIVENESS OF STATIN PRIORITISATION BASED ON ABSOLUTE RISK REDUCTION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
    Kohli-Lynch, C. N.
    Moran, A. E.
    Thanassoulis, G.
    Sniderman, A. D.
    Zhang, Y.
    Pencina, M.
    Pletcher, M. J.
    Vittinghoff, E.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A614 - A614
  • [38] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [39] Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study
    Linda J Cobiac
    Anne Magnus
    Jan J Barendregt
    Rob Carter
    Theo Vos
    [J]. BMC Public Health, 12
  • [40] COST-EFFECTIVENESS OF EICOSAPENTAENOIC ACID (EPA) ON PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
    Kodera, S.
    Kiyosue, A.
    Ando, J.
    Komuro, I
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A614 - A614
12345